The estimated Net Worth of Rock Ventures Ii, L.P.Third... is at least 421 百万$ dollars as of 7 February 2017. Rock Third owns over 1,000,000 units of Blueprint Medicines Corp stock worth over 385,516,860$ and over the last 10 years Rock sold BPMC stock worth over 35,280,000$.
Rock has made over 1 trades of the Blueprint Medicines Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently Rock sold 1,000,000 units of BPMC stock worth 35,280,000$ on 7 February 2017.
The largest trade Rock's ever made was selling 1,000,000 units of Blueprint Medicines Corp stock on 7 February 2017 worth over 35,280,000$. On average, Rock trades about 166,667 units every 0 days since 2015. As of 7 February 2017 Rock still owns at least 4,453,753 units of Blueprint Medicines Corp stock.
You can see the complete history of Rock Third stock trades at the bottom of the page.
Rock's mailing address filed with the SEC is 29 Newbury St #301, Boston, MA 02116, USA.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over 126,865,732$ worth of Blueprint Medicines Corp stock and bought 131,110 units worth 2,599,105$ . The most active insiders traders include Llc Fmr、Kevin P Starr、Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of 1,362,195$. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth 1,685,900$.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: